好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Novel Electrophysiological and Ultrasound Biomarkers for Trigger Point Assessment
Neuromuscular and Clinical Neurophysiology (EMG)
P1 - Poster Session 1 (8:00 AM-9:00 AM)
11-018

To evaluate the feasibility of three new, objective measurements for characterizing trigger points (TrPs).

Although TrPs affect millions of individuals, we do not understand the mechanisms underlying the course of this condition. Furthermore, most pain studies rely on subjective patient scores as the primary outcome. To address these gaps, we aim to employ three entirely objective and quantitative assessment methodologies to assess these entities.

Here we present results from our first group of healthy subjects whose data have been analyzed for repeatability. This novel data set will assist us in moving toward full implementation of a standardized TrP assessment protocol.

We performed testing of the three modalities on the right trapezius muscle in healthy participants during two separate visits. Electrical impedance myography (EIM) noninvasively evaluates muscle properties using a painless electrical current. Quantitative muscle ultrasound images translate the brightness of muscle scans into a numerical value, the grayscale level. Myofiber excitability testing (MET) quantifies changes in muscle fiber conduction properties in response to various electrical conditioning stimuli. Intra-class coefficients (ICCs), Bland-Altman analysis and mean percent difference were calculated as a reflection of reliability for each of these modalities.

Sixteen healthy participants (10 men, 6 women) with mean age±SD 52.6±16.7 years were enrolled. There was a strong intraclass correlation for the EIM phase angle values between first and second visit, ICC = 0.96, and a mean percent difference of 9.35±8.89%. Reproducibility of grayscale also demonstrated positive correlation between the visits, ICC = 0.92, with mean percent difference 4.47±3.78%, as did MET with mean percent difference 3.47±0.37%.

The initial findings indicate the promising use of EIM, grayscale, and MET as potential diagnostic biomarkers for TrPs.

Authors/Disclosures
Sarah Verga (Beth Israel Deaconess Medical Center)
PRESENTER
Miss Verga has nothing to disclose.
Ajitesh Nanda (Beth Israel Deaconess Medical Center) Ajitesh Nanda has nothing to disclose.
Askhat Mukushev (Beth Israel Deaconess Medical Center) Askhat Mukushev has nothing to disclose.
Soleil Samaan (Beth Israel Deaconess Medical Center) No disclosure on file
Courtney E. McIlduff, MD (Beth Israel Deaconess Medical Center) The institution of Dr. McIlduff has received research support from NIH - R21NSNS118434. The institution of Dr. McIlduff has received research support from NIH - R01MH111875. The institution of Dr. McIlduff has received research support from Blavatnik Family Fund. Dr. McIlduff has received publishing royalties from a publication relating to health care.
Brian Wainger, MD, PhD (Massachusetts General Hospital) Dr. Wainger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Quralis. Dr. Wainger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Apic Bio. Dr. Wainger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Wainger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Wainger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Quralis. Dr. Wainger has stock in Quralis. The institution of Dr. Wainger has received research support from Argenx. The institution of Dr. Wainger has received research support from Sanofi. Dr. Wainger has received intellectual property interests from a discovery or technology relating to health care.
Jim Wu No disclosure on file
Hannah Mu No disclosure on file
Seward B. Rutkove, MD, FAAN Dr. Rutkove has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Myolex, Inc. Dr. Rutkove has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neuorlogy . The institution of Dr. Rutkove has received research support from NIH. The institution of Dr. Rutkove has received research support from NASA. The institution of Dr. Rutkove has received research support from Blavatnik Family Foundation. Dr. Rutkove has received intellectual property interests from a discovery or technology relating to health care. Dr. Rutkove has received intellectual property interests from a discovery or technology relating to health care. Dr. Rutkove has received publishing royalties from a publication relating to health care. Dr. Rutkove has received publishing royalties from a publication relating to health care. Dr. Rutkove has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with NIH.